ACXP vs. INDP, AYTU, SGMT, CNTX, RNAC, PRQR, INCR, RZLT, CYBN, and RAPT
Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Indaptus Therapeutics (INDP), Aytu BioPharma (AYTU), Sagimet Biosciences (SGMT), Context Therapeutics (CNTX), Cartesian Therapeutics (RNAC), ProQR Therapeutics (PRQR), InterCure (INCR), Rezolute (RZLT), Cybin (CYBN), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Acurx Pharmaceuticals (NASDAQ:ACXP) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk.
Indaptus Therapeutics' return on equity of -108.14% beat Acurx Pharmaceuticals' return on equity.
Acurx Pharmaceuticals presently has a consensus target price of $12.00, suggesting a potential upside of 378.09%. Indaptus Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 406.33%. Given Indaptus Therapeutics' higher possible upside, analysts plainly believe Indaptus Therapeutics is more favorable than Acurx Pharmaceuticals.
11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 35.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Acurx Pharmaceuticals has a beta of -1.79, indicating that its share price is 279% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
In the previous week, Indaptus Therapeutics had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Indaptus Therapeutics and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.87 beat Indaptus Therapeutics' score of 1.03 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals received 1 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. Likewise, 91.67% of users gave Acurx Pharmaceuticals an outperform vote while only 83.33% of users gave Indaptus Therapeutics an outperform vote.
Summary
Acurx Pharmaceuticals beats Indaptus Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Acurx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acurx Pharmaceuticals Competitors List
Related Companies and Tools
